Publication

SOHO •
4 September, 2025 •
•

Hematologic response in patients with myelofibrosis treated with pacritinib in real-word clinical settings

Raajit Rampal, Samantha Eiffert, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Anupama Vasudevan, Michael Vredenburg , John Mascarehnas

Available materials

Poster

Publication

SOHO •
3 September, 2025 •
•

Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib previously treated with ruxolitinib

John Mascarehnas, Samantha Eiffert, Michael Marrone, Lisa Morere, Abiola Oladapo, Anubhav Sharma, Purvi Suthar, Anupama Vasudevan, Michael Vredenburg , Raajit Rampal

Available materials

Poster

Publication

EHA •
15 June, 2025 •
•

Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x10^9/L at PAC initiation: Interim results from the MY-PAC Study

Doug Tremblay, Abiola Oladapo, Emily Levine, Michael Marrone, Djibril Liassou, Purvi Suthar, Adina Geprifti, Gerard Hoehn, Michael Vredenburg , Bruce Feinberg, Naveen Pemmaraju, James Rossetti

Available materials

Poster

Publication

Cytopenia is associated with real-world disease progression and diminished survival in patients with myelofibrosis: Analysis of a US national administrative claims database

Hematologic response in patients with myelofibrosis treated with pacritinib in real-word clinical settings

Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib previously treated with ruxolitinib

Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x10^9/L at PAC initiation: Interim results from the MY-PAC Study

Real-world effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with pacritinib compared to best available therapy based on PERSIST-2 trial